WallStSmart
INDP

Indaptus Therapeutics Inc

NASDAQ: INDP · HEALTHCARE · BIOTECHNOLOGY

$1.75
+2.79% today

Updated 2026-06-03

Market cap
$414.47M
P/E ratio
P/S ratio
EPS (TTM)
$-12.70
Dividend yield
52W range
$1 – $20
Volume
0.1M

Indaptus Therapeutics Inc (INDP) Financial statements

SEC filings — annual and quarterly data.

Profit margin
0.00%
Operating margin
0.00%
ROE
-932.00%
ROA
-286.80%
Debt/equity

Margin trends — annual

Gross margin Operating margin Profit margin
YearRevenueNet incomeGross marginOp. marginProfit margin
2008$-5.36M
2009$-3.94M
2010$-5.42M
2011$-7.58M
2012$-5.18M
2013$-5.09M
2014$-5.69M
2015$-7.18M
2016$-13.36M
2017$-28.91M
2018$-43.54M
2019$-47.60M
2020$0.00$-3.58M
2021$0.00$-7.71M
2022$0.00$-14.32M
2023$0.00$-15.42M
2024$0.00$-15.02M
2025$0.00$-20.85M

Frequently asked questions

How much free cash flow does INDP generate?

INDP produced $-14.82M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is INDP's balance sheet healthy?

INDP holds $8.51M in cash and equivalents against — in long-term debt, on $3.15M of shareholder equity. That debt is best read against the cash flow the business throws off each year.